HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Zacks Rank    Equity Research    Premium Home    My Account    Help    
Learn more
Self Investors Wanted Today

Few spots available. Master Zacks' market-tripling Stock Picking Method in your home at our cost.
Opportunity ends Saturday, Nov. 21 >>

Quote:
Login Free Membership
Search:

 
Analyst Blog  

Somaxon with Cash Problems

March 13, 2009 | Comments: 0
Recommended this article (1)
Print    Share

On February 26, 2009, the U.S. FDA issued a Complete Response Letter (CRL) to Somaxon Pharmaceuticals, Inc. (SOMX - Analyst Report) to the new drug application (NDA) for Silenor (doxepin) for the treatment of insomnia.

Based on its review, the FDA has determined that the NDA cannot be approved in its present form. Somaxon will meet with the FDA in early April 2009 to discuss a path forward. In the meantime, the company's cash position is a major concern.

Somaxon will run out of cash sometime around the middle of the year. Management must do some sort of transaction to raise cash in the next few months. At this point, visibility is low and our recommendation is for investors to avoid the name.

Email

Print

Share

RSS

Rate Pos

Rate Neg

Comment
Read/Post Comments (0) | Recommended this article (1)
 Posting Comment...
There was a problem posting this this comment. Please try back later.
[CLICK TO CLOSE X]
Comments (Limit 1000 Characters - Used: 0)
Display Name: Email Address:  
 Loading Comments...
Be the first to comment on this article!
Best Stocks. Best Insight. Join Now...it's FREE!
Over 550,000 investors look forward to the timely insights in our email newsletter; Zacks Profit from the Pros. In each daily issue you will find:
  • Free  Four Zacks #1 Rank "Strong Buy" Stocks
  • Free  Timely Market Commentary
  • Free  Wealth Management Tips
  • Free  Profitable Strategy Screens
  • Free  Bull and Bear Stocks of the Day
Zacks FREE Registration

More Zacks Resources

Market Summary Nov 22, 2009 02:01 am ET
DJIA 10318.16  -14.28 -0.14%
NASD 2146.04  -10.78 -0.50%
S&P 500 1091.38  -3.52 -0.32%
Sponsored Links